# Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

> **NCT05802264** · PHASE1 · RECRUITING · sponsor: **Cystetic Medicines, Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **COMBINATION_PRODUCT:** ABCI
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT05802264
- **Lead sponsor:** Cystetic Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-21
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05802264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05802264, "Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05802264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*